Atria Investments Inc Takes Position in Maximus, Inc. $MMS

Atria Investments Inc bought a new position in shares of Maximus, Inc. (NYSE:MMS) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 3,490 shares of the health services provider’s stock, valued at approximately $245,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Arkadios Wealth Advisors acquired a new stake in Maximus during the second quarter worth approximately $356,000. Envestnet Asset Management Inc. increased its stake in shares of Maximus by 23.9% during the second quarter. Envestnet Asset Management Inc. now owns 32,705 shares of the health services provider’s stock worth $2,296,000 after purchasing an additional 6,318 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in Maximus by 6.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 6,884 shares of the health services provider’s stock worth $483,000 after purchasing an additional 423 shares during the last quarter. Keeler Thomas Management LLC bought a new stake in Maximus in the 2nd quarter valued at $1,179,000. Finally, AlphaQuest LLC grew its holdings in Maximus by 142.0% in the 2nd quarter. AlphaQuest LLC now owns 8,663 shares of the health services provider’s stock valued at $608,000 after buying an additional 5,083 shares in the last quarter. Institutional investors and hedge funds own 97.21% of the company’s stock.

Insiders Place Their Bets

In related news, insider Michelle F. Link sold 1,610 shares of the firm’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $90.86, for a total transaction of $146,284.60. Following the completion of the transaction, the insider directly owned 13,508 shares of the company’s stock, valued at $1,227,336.88. This trade represents a 10.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms recently commented on MMS. Zacks Research downgraded shares of Maximus from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 27th. Weiss Ratings upgraded shares of Maximus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Maximus presently has an average rating of “Moderate Buy” and an average target price of $90.00.

Maximus Trading Down 2.4%

MMS opened at $80.54 on Thursday. Maximus, Inc. has a fifty-two week low of $63.77 and a fifty-two week high of $92.50. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.27 and a quick ratio of 2.27. The firm has a market capitalization of $4.54 billion, a price-to-earnings ratio of 14.83 and a beta of 0.57. The company’s 50 day moving average price is $87.00 and its two-hundred day moving average price is $78.91.

Maximus Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $1.20 annualized dividend and a dividend yield of 1.5%. Maximus’s payout ratio is currently 22.10%.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.